Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

NCT02263508 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

713

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Talimogene Laherparepvec
DRUG: Pembrolizumab
DRUG: Placebo

Sponsor

Amgen

Collaborators

[object Object]